menu
    • menu
    [{"orgOrder":0,"company":"Arrivent","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Furmonertinib","moa":"EGFR","graph1":"Oncology","graph2":"Approved","graph3":"Arrivent","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Arrivent \/ Hillhouse Capital Group","highestDevelopmentStatusID":"12","companyTruncated":"Arrivent \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Arrivent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"pan-EGFR mutant","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arrivent \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Not Applicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Sofinnova","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"","sponsorNew":"Arrivent \/ Sofinnova","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Sofinnova"},{"orgOrder":0,"company":"Arrivent","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"Arrivent \/ Arrivent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Not Applicable"},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Arrivent","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Furmonertinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arrivent","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Arrivent \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Arrivent \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Arrivent","sponsor":"Alphamab Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Arrivent","amount2":0.62,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.62,"dosageForm":"","sponsorNew":"Arrivent \/ ArriVent","highestDevelopmentStatusID":"2","companyTruncated":"Arrivent \/ ArriVent"},{"orgOrder":0,"company":"Arrivent","sponsor":"Aarvik Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Arrivent","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Arrivent \/ ArriVent","highestDevelopmentStatusID":"14","companyTruncated":"Arrivent \/ ArriVent"}]

    Find Clinical Drug Pipeline Developments & Deals by Arrivent

    Menu

    Arrivent

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Aarvik Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

                            Details : ArriVent will be responsible for clinical development and commercialization of a novel ADC molecule, for oncology indications, that relies on the unique modular platform developed by Aarvik.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Aarvik Therapeutics

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Alphamab Oncology

                            Deal Size : $615.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

                            Details : Through the collaboration, both companies will leverage Alphamab’s proprietary linker-payload platform and glycan-conjugation technology to identify novel ADCs for oncology indications.

                            Brand Name : Undiclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 05, 2024

                            Lead Product(s) : Antibody-drug Conjugate

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Alphamab Oncology

                            Deal Size : $615.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co.

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ArriVent Announces Pricing of Upsized Initial Public Offering

                            Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co.

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Goldman Sachs & Co.

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA

                            Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Goldman Sachs & Co.

                            Deal Size : $135.7 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced ...

                            Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 30, 2023

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : InnoCare Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InnoCare and ArriVent Announce Clinical Development Collaboration

                            Details : Under the agreement, InnoCare and ArriVent will jointly evaluate the anti-tumor activity and safety of ICP-189, a novel SHP2 allosteric inhibitor, combined with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in...

                            Brand Name : ICP-189

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 13, 2023

                            Lead Product(s) : ICP-189,Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : InnoCare Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Sofinnova

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing

                            Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Sofinnova

                            Deal Size : $155.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or M...

                            Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 05, 2022

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Arrivent

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Hillhouse Capital Group

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            ArriVent Biopharma Launches With Up to $150M in Series A Financing and Strategic Licensing Agreement for Clini...

                            Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.

                            Brand Name : AST2818

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 30, 2021

                            Lead Product(s) : Furmonertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Hillhouse Capital Group

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth